Original title: Taiwanese media: The Taiwanese authorities say it will OEM Modena vaccine. Expert: It’s impossible to imagine a fantasy!
[环球网报道 记者 康博浩]According to “United News Network” news, it was recently reported that the Epidemic Command Center in Taiwan is actively negotiating the manufacturing of Modena vaccines, and Taiwan’s “National Institute of Health” is preparing for the “Second Vaccine Plant” and is also looking forward to signing a contract with Modena for mass production. Authorization. Everything seems to be going smoothly, but the former “Director of Disease Control” Su Yiren said, “This is a fantasy.” Last year, the DPP authorities called for self-produced masks, but the threshold for mask technology is extremely low and mRNA (messenger ribonucleic acid) vaccine technology is difficult. According to Taiwan’s existing technology and energy, it’s like painting a pie in the sky, and it feels just as cool.
Su Yiren said that every vaccine factory has a fixed vaccine production line, and it is necessary for these listed companies to abandon their original production lines and change them to mRNA vaccines. He said: Unless all are taken back and integrated by the Taiwan authorities, it will be possible.
According to the report, Su Yiren pointed out two major problems. Taiwan has never developed an mRNA vaccine, and the front-end production technology is blank. In addition, the vaccine energy is not enough. There are reports that the DPP authorities want to “produce three to five in six to nine months. Hundreds of millions of doses of Modena vaccine“, this bull is blowing too much, and the insider knows that this is impossible when he hears it.
Su Yiren said that the mRNA vaccine is a brand-new technology. A small amount of cell culture may not be a problem, but it is quite difficult to grow from 5 ml to 50 ml. If you want to make large quantities, make 50 ml, 100 ml, or 200 ml. Even five hundred liters, two thousand liters and other raw materials, the challenge for each step is quite large, “the more the quantity, the higher the difficulty.”
According to the report, Liu Jiaqi, an associate researcher at the Institute of Infectious Diseases and Vaccines of the National Health Institute, said that how to wrap mRNA into a lipid film and send it into the human body is the biggest technical challenge at present, and it is Modena’s most powerful technology. It is also the part that Taiwan must learn and learn from. In addition, Taiwan also needs to develop systems such as related adjuvants, so that once an outbreak occurs, it can manufacture it on its own. Su Yiren believes that unless the original Modena factory sends personnel to the “National Health Institute” and provides full technical support, Taiwanese manufacturers can at most fill this piece.
According to reports, production capacity is another big problem. Su Yiren said that as early as April last year, the “Epidemic Prevention Innovation Alliance (CEPI)”, which participated in the creation of the COVAX (New Coronary Pneumonia Vaccine Implementation Plan) platform, sent people to Taiwan to learn about Taiwan’s biotechnology. Manufacturers can produce vaccines, and at that time, it was estimated that only 10 million doses of new crown vaccine could be produced in a month. The island’s vaccine production capacity is limited, which explains why the command center negotiated with AstraZeneca Vaccine last August to break the contract.
Su Yiren also mentioned that the three major vaccine factories on the island, such as “Guoguang, Lianya, and High-end”, are actively developing their own new crown vaccines, and the production lines that can be moved are very limited. As for another manufacturer, “Tai Kang”, the production capacity is not large. The command center wants to gather the power of the factories on the island to produce 300 to 500 million doses of mRNA vaccine within six to nine months. This is absolutely impossible.
Su Yiren said frankly that “producing mRNA vaccines is not a simple matter.” Modena only produced tens of millions of doses at the end of last year. After overcoming many problems, it gradually expanded its production capacity this year. In addition, South Korea’s successful acquisition of mRNA vaccines was due to political factors. The large scale of the “Samsung Bio” plant was the main factor. However, even so, South Korea only negotiated cooperation in the back-end aseptic filling, labeling and packaging. Whether technology transfer is still unknown.
.